ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
89
HLB’s Chinese partner to present efficacy of rivoceranib at ESMO meeting
admin
2021.09.14
88
HLB to present results of rivoceranib at global lung cancer meeting
admin
2021.09.02
87
Hwajin, a subsidiary of HLB, gained the U.S. FDA's approval for Sofjec syringes
admin
2021.08.24
86
Elevar Therapeutics Announces Orphan Drug Designation for Rivoceranib (Apatinib) for the Treatment of Adenoid Cystic Carcinoma (ACC)
admin
2021.02.09
85
Elevar Therapeutics announces Licensing Agreement with Inceptua Group for commercialization of Apealea® (Paclitaxel Micellar) in Europe
admin
2020.12.27
84
Rivoceranib showed 'complete remission' in a combination clinical trial of refractory hepatocellular carcinoma.
admin
2020.12.10
83
HLB confirms "excellent treatment effect for breeding” in combination therapy of Rivoceranib and Opdivo
admin
2020.11.20
82
Elevar Therapeutics announces Early Completion of Initial Target Enrollment in Pivotal Phase 2 Study Evaluating Rivoceranib (Apatinib) in Adenoid Cystic Cancer (ACC)
admin
2020.11.18
81
Rivoceranib gets the 'Approval for Therapeutic Use' for Terminal Gastric Cancer Patients
admin
2020.10.21
80
Rivoceranib selected as a 'Highlight' of ESMO 2020 by the European Association
admin
2020.10.07
1
2
3
4
5
6
7
8
9
10
>
>>